This is a comprehensive reference survey on the identification and development of promising cancer chemopreventive agents that will help stimulate further novel research and new approvable drugs. For each agent, the authors review the relevant mechanisms of action, the criteria for populations benefiting from intervention, the safety and pharmacodynamics, clinical study design emphasizing the use of precancers, and early associated cellular and molecular biomarkers of carcinogenesis. The pharmacologic and/or mechanistic classes discussed range from antimutagens, antiinflammatories, and the nuclear receptor superfamily, to signal transduction modulators, antioxidants, vitamins, and minerals. The overall focus is on molecular targets and mechanisms. A second volume, "Strategies in Chemoprevention", describes the exciting methodologies that will accelerate progress in this field and discusses the state of clinical development of chemoprevention in the various human cancer target organs.

Despite significant advances in cancer treatment and measures of neoplastic progression, drug effect (or early detection, overall cancer incidence has increased, pharmacodynamic markers), and markers that measure cancer-associated morbidity is considerable, and overall prognosis as well as predict responses to specific therapy. cancer survival has remained relatively flat over the past All these biomarkers have the potential to greatly augment several decades (1,2). However, new technology the development of successful chemoprevention therapies, allowing exploration of signal transduction pathways, but two specific types of biomarkers will have the most identification of cancer-associated genes, and imaging of immediate impact on successful chemopreventive drug tissue architecture and molecular and cellular function is development-those that measure the risk of developing increasing our understanding of carcinogenesis and cancer invasive life-threatening disease, and those whose mo- progression. This knowledge is moving the focus of cancer lation can "reasonably predict" clinical benefit and, therapeutics, including cancer preventive treatments, to therefore, serve as surrogate endpoints for later-occurring drugs that take advantage of cellular control mechanisms clinical disease. Thus far, the biomarker that best measures to selectively suppress cancer progression. these two phenomena is intraepithelial neoplasia (IEN) Carcinogenesis is now visualized as a multifocal, because it is a near obligate precursor to cancer.

A comprehensive reference survey on the identification and development of promising cancer chemopreventive agents that will help stimulate further novel research and new approvable drugs. For each agent, the authors review the relevant mechanisms of action, the criteria for populations benefiting from intervention, the safety and pharmacodynamics, clinical study design emphasizing the use of precancers, and early associated cellular and molecular biomarkers of carcinogenesis. The pharmacologic and/or mechanistic classes discussed range from antimutagens, antiinflammatories, and the nuclear receptor superfamily, to signal transduction modulators, antioxidants, vitamins, and minerals. The overall focus is on molecular targets and mechanisms. A second volume, Strategies in Chemoprevention, describes the exciting methodologies that will accelerate progress in this field and discusses the state of clinical development of chemoprevention in the various human cancer target organs.

Despite significant advances in cancer treatment and measures of neoplastic progression, drug effect (or early detection, overall cancer incidence has increased, pharmacodynamic markers), and markers that measure cancer-associated morbidity is considerable, and overall prognosis as well as predict responses to specific therapy. cancer survival has remained relatively flat over the past All these biomarkers have the potential to greatly augment several decades (1,2). However, new technology the development of successful chemoprevention therapies, allowing exploration of signal transduction pathways, but two specific types of biomarkers will have the most identification of cancer-associated genes, and imaging of immediate impact on successful chemopreventive drug tissue architecture and molecular and cellular function is development-those that measure the risk of developing increasing our understanding of carcinogenesis and cancer invasive life-threatening disease, and those whose mo- progression. This knowledge is moving the focus of cancer lation can "reasonably predict" clinical benefit and, therapeutics, including cancer preventive treatments, to therefore, serve as surrogate endpoints for later-occurring drugs that take advantage of cellular control mechanisms clinical disease. Thus far, the biomarker that best measures to selectively suppress cancer progression. these two phenomena is intraepithelial neoplasia (IEN) Carcinogenesis is now visualized as a multifocal, because it is a near obligate precursor to cancer.